insulin degludec vs insulin icodec
Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.
Type 2 Diabetes
Shared mechanism: Insulin receptor (basal) · full Type 2 Diabetes pipeline
insulin degludec · Tresiba
Marketed by Novo Nordisk
NCT00982644 · Phase 3 · completed
The trial was randomized and actively controlled, with 1,030 participants, but it was not blinded and its primary endpoint was the surrogate measure of change in HbA1c rather than a hard clinical outcome. HbA1c changed by -1.06% with insulin degludec versus -1.19% with insulin glargine, but no statistical comparison is reported, so whether the primary endpoint was met is unclear.
Next expected readout: June 2027 · NCT07173712 (registry estimate)
Reported efficacy
Main Trial (Primary Endpoint): Change in Glycosylated Haemoglobin (HbA1c) After 52 Weeks of Treatment (Week 0, Week 52); Extension Trial (Primary Endpoint): Rate of Confirmed Hypoglycaemic Episodes (Week 0 to Week 104 + 7 days follow up); Extension Trial (Primary Endpoint): Rate of Nocturnal Confirmed Hypoglycaemic Episodes (Week 0 to Week 104 + 7 days follow up); Extension Trial (Primary Endpoint): Rate of Treatment Emergent Adverse Events (AEs) (Week 0 to Week 104 + 7 days of follow up): Main Trial (Primary Endpoint): Change in Glycosylated Haemoglobin (HbA1c) After 52 Weeks of Treatment (Week 0, Week 52): IDeg OD -1.06 percentage of glycosylated haemoglobin (Standard Deviation 1.01) vs IGlar OD -1.19 percentage of glycosylated haemoglobin (Standard Deviation 0.97) (unclear)
Result source: NCT00982644
insulin icodec · Awiqli
Marketed by Novo Nordisk
NCT04760626 · Phase 3 · completed
The study was randomized and actively controlled, but it was open-label, with 542 participants assigned to insulin icodec and 543 to once-daily basal insulin analogues. The primary HbA1c endpoint was met for non-inferiority, but HbA1c is a surrogate measure rather than a hard clinical or endoscopic endpoint, supporting a moderate evidence grade.
Next expected readout: October 2027 · NCT07747402 (registry estimate)
Reported efficacy
Change in Glycated Haemoglobin (HbA1c) (Week 0, Week 26): Change in Glycated Haemoglobin (HbA1c) (Week 0, Week 26): Insulin Icodec -0.84 Percentage (%) point (Standard Deviation 0.83) vs Insulin Glargine -0.58 Percentage (%) point (Standard Deviation 0.89) (met)
Result source: NCT06340854
Results for Type 2 Diabetes
Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.
| Key endpoint | insulin degludec | insulin icodec |
|---|---|---|
| HbA1c, change | -1.1% vs -1.2%vs IGlarNCT0098264422 other results
| -1.7% vs -1.3%vs Once Daily Basal Insulin AnalogueNCT0476062611 other results
|
| Body weight, change (kg) | 2.9 vs -1vs LiraglutideNCT0260730615 other results
| 2.3 vs 1.8vs Insulin GlargineNCT0446088510 other results
|
| HbA1c below 7% | 75.3% vs 35.6%vs Liraglutide or ExenatideNCT01676116 | —Not posted · NCT05013229 |
| Fasting plasma glucose, change | -4.1 vs -2.6vs LiraglutideNCT0260730615 other results
| -3.4 vs -3.3vs Insulin GlargineNCT044608859 other results
|
| 3-point MACE (% with event) | —Not posted · NCT05802862 | —Not posted · NCT05013229 |
HbA1c, change
- insulin degludec
- -1.1% vs -1.2%vs IGlarNCT00982644
22 other results
- -2.4% vs -1.8% NCT02607306
- -1.8% vs -1.8% NCT02607306
- -1.4% vs -1.6% NCT04795531
- -1.7% vs -1.2% NCT03172494
- -1.2% vs -1.2% NCT03172494
- -1.9% vs -1.1% NCT03175120
- -1.5% vs -1.4% NCT02762578
- -0.1% vs -0.1% NCT03268005
- -1.9% vs -0.7% NCT02911948
- -1.5% vs -1.5% NCT02420262
- -1.8% vs -1.1% NCT01952145
- -1.3% vs -0.4% NCT01676116
- -0.6% vs -0.5% NCT04588259
- -0.1% vs -0.1% NCT01570751
- -1.1% vs -1.1% NCT02648217
- -0.9% vs -0.8% NCT01959529
- -2.4% vs -1.8% NCT02607306
- -1.8% vs -1.8% NCT02607306
- -2.0% vs -1.7% NCT02501161
- -0.5% vs -0.5% NCT03078478
- -0.9% vs -1.1% NCT00982644
- -0.5% vs 0% NCT04538352
- insulin icodec
- -1.7% vs -1.3%vs Once Daily Basal Insulin AnalogueNCT04760626
11 other results
- -1.6% vs -1.4% NCT04460885
- -0.8% vs -0.6% NCT06340854
- -1.6% vs -1.4% NCT04795531
- -0.9% vs -0.7% NCT04770532
- -1.2% vs -1.2% NCT04880850
- -1.3% vs -1.1% NCT03751657
- -0.5% vs -0.5% NCT03922750
- -0.8% vs -0.5% NCT03922750
- -1% vs -1.0% NCT03951805
- -1.2% vs -1.0% NCT03951805
- -1.4% vs -1.0% NCT03951805
Body weight, change (kg)
- insulin degludec
- 2.9 vs -1vs LiraglutideNCT02607306
15 other results
- 4.1 vs -1 NCT02607306
- 2.3 vs 2.8 NCT04795531
- 0.2 vs -2.5 NCT03172494
- 0.5 vs 2.2 NCT02501161
- 2.8 vs 2.2 NCT02762578
- -0.9 vs 2.6 NCT02420262
- -1.4 vs 1.8 NCT01952145
- 2.9 vs 1.7 NCT03078478
- 1.2 vs 1.1 NCT03268005
- 1.3 vs -2.5 NCT03172494
- -0.7 vs 0.5 NCT03175120
- 1.2 vs 3 NCT02501161
- -0.7 vs 0.7 NCT02911948
- 2 vs -0.8 NCT01676116
- -8.6 vs 1.4 NCT04538352
- insulin icodec
- 2.3 vs 1.8vs Insulin GlargineNCT04460885
10 other results
- 2.0 vs 0.6 NCT06340854
- 2.8 vs 2.3 NCT04795531
- 1.4 vs -0.3 NCT04770532
- 2.7 vs 2.2 NCT04880850
- 1.5 vs 1.6 NCT03751657
- 1.3 vs 0.1 NCT03922750
- 0.6 vs 0.1 NCT03922750
- 0.9 vs 0.6 NCT03951805
- 1.1 vs 0.6 NCT03951805
- 1.3 vs 0.6 NCT03951805
HbA1c below 7%
- insulin degludec
- 75.3% vs 35.6%vs Liraglutide or ExenatideNCT01676116
- insulin icodec
- —Not posted · NCT05013229
Fasting plasma glucose, change
- insulin degludec
- -4.1 vs -2.6vs LiraglutideNCT02607306
15 other results
- -4.0 vs -2.6 NCT02607306
- -3.0 vs -3.0 NCT04795531
- -3.6 vs -1.9 NCT03172494
- -4.0 vs -3.8 NCT02501161
- -3.0 vs -1.6 NCT02762578
- -3.0 vs -0.6 NCT01676116
- -2.0 vs -1.4 NCT03078478
- 0.6 vs 0.7 NCT03268005
- -3.5 vs -1.9 NCT03172494
- -3.6 vs -2.8 NCT03175120
- -3.9 vs -3.7 NCT02501161
- -2.8 vs -2.3 NCT02911948
- 0.4 vs 0.2 NCT04588259
- -0.8 vs 0 NCT01570751
- -2 vs -4.4 NCT02648217
- insulin icodec
- -3.4 vs -3.3vs Insulin GlargineNCT04460885
9 other results
- -3.0 vs -3.0 NCT04795531
- -1.6 vs -1.6 NCT04770532
- -1.8 vs -1.6 NCT04880850
- -3.2 vs -3.0 NCT03751657
- -0.8 vs -0.6 NCT03922750
- -0.7 vs -0.6 NCT03922750
- -2.2 vs -2.3 NCT03951805
- -2.4 vs -2.3 NCT03951805
- -3.0 vs -2.3 NCT03951805
3-point MACE (% with event)
- insulin degludec
- —Not posted · NCT05802862
- insulin icodec
- —Not posted · NCT05013229
- Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
- An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.
6 other shared endpoints and safety
Coverage. insulin degludec: 10 of 10 rows · insulin icodec: 10 of 10 rows. A dash means no reviewed, structured value is available for that endpoint in this indication.
| Reported metric | insulin degludec Rows use multiple source trials | insulin icodec Rows use multiple source trials |
|---|---|---|
| HbA1c absolute change · percentage points No placebo or comparator arm | -2.02% (n=200) @ 32wka,b,c,d NCT02298192 · Phase 3 · registry result, not featured evidence show 1 more dose-2.01% (n=189) @ 32wk NCT02298192 · Phase 3 · registry result, not featured evidence | -1.23% (n=91) @ 52wkb,c,d NCT05813912 · Phase 3 · registry result, not featured evidence · combination |
| HbA1c Change mmol/Mol absolute change · mmol/mol | -6.18 vs -5.89 NovoRapid mmol/mol @ 16wke,f,c,g NCT04588259 · Phase 3 · registry result, not featured evidence | -14.51 vs -12.54 Insulin Glargine mmol/mol @ 26wke,f,c,g NCT03751657 · Phase 2 · registry result, not featured evidence |
| Hypoglycemia Episodes Level 2 event count · count | 23 vs 53 Insulin Icodec count @ 31wkb,c NCT04795531 · Phase 3 · registry result, not featured evidence | 53 vs 23 Insulin Degludec count @ 31wkb,c NCT04795531 · Phase 3 2 other source trials113 vs 41 Insulin Degludec count @ 31wk NCT04770532 · Phase 3 937 vs 935 Insulin Glargine count @ 31wk NCT04880850 · Phase 3 |
| Hypoglycemia Episodes Level 2 or 3 event count · count | 25 vs 53 Insulin Icodec count @ 31wkb,c NCT04795531 · Phase 3 · registry result, not featured evidence | 53 vs 25 Insulin Degludec count @ 31wkb,c NCT04795531 · Phase 3 2 other source trials113 vs 42 Insulin Degludec count @ 31wk NCT04770532 · Phase 3 944 vs 938 Insulin Glargine count @ 31wk NCT04880850 · Phase 3 |
| Hypoglycemia Episodes Level 3 event count · count | 280 vs 472 Insulin Glargine countb,c,h NCT01959529 · Phase 3 1 other source trial2 vs 0 Insulin Icodec count @ 31wk NCT04795531 · Phase 3 · registry result, not featured evidence | 0 vs 2 Insulin Degludec count @ 31wkb,c,h NCT04795531 · Phase 3 2 other source trials0 vs 1 Insulin Degludec count @ 31wk NCT04770532 · Phase 3 7 vs 3 Insulin Glargine count @ 31wk NCT04880850 · Phase 3 |
| SMBG 9-point absolute change · mmol/L | -3.84 vs -3.46 Liraglutide mmol/L @ 52wka,e,b,c,i NCT02607306 · Phase 3 · registry result, not featured evidence show 1 more dose-4.6 vs -3.46 Liraglutide mmol/L @ 52wk NCT02607306 · Phase 3 · registry result, not featured evidence | -2.7 vs -2.26 Insulin Glargine mmol/L @ 26wke,b,c,i NCT03751657 · Phase 2 · registry result, not featured evidence |
| Dropout rate | 21.5%once dailyj NCT00982644 · Phase 3 · monotherapy · Type 2 Diabetes · phase 3 show 25 more results2% NCT01959529 · Phase 3 0%once weekly NCT04538352 · Phase 4 · registry result, not featured evidence · combination 10.9% NCT03336528 · Phase 4 · registry result, not featured evidence — NCT04588259 · Phase 3 · registry result, not featured evidence 2.7% NCT04795531 · Phase 3 · registry result, not featured evidence 6.7%Insulin Degludec NCT03172494 · Phase 3 · registry result, not featured evidence 5.5%Insulin Degludec/Liraglutide NCT03172494 · Phase 3 · registry result, not featured evidence 4% NCT03175120 · Phase 3 · registry result, not featured evidence — NCT03078478 · Phase 3 · registry result, not featured evidence 2.7% NCT03268005 · Phase 3 · registry result, not featured evidence 4.3% NCT02501161 · Phase 3 · registry result, not featured evidence 2.2% NCT02906917 · Phase 3 · registry result, not featured evidence 8.5%Insulin Degludec NCT02607306 · Phase 3 · registry result, not featured evidence 7.6%Insulin Degludec/Liraglutide NCT02607306 · Phase 3 · registry result, not featured evidence 0% NCT02911948 · Phase 3 · registry result, not featured evidence 4.8% NCT02773368 · Phase 3 · registry result, not featured evidence 4.2%BID NCT02762578 · Phase 3 · registry result, not featured evidence 0.8% NCT02420262 · Phase 3 · registry result, not featured evidence 7.6%twice daily NCT02648217 · Phase 3 · registry result, not featured evidence 2.9%IDegLira NCT02298192 · Phase 3 · registry result, not featured evidence 9%IDegLira (1WT) NCT02298192 · Phase 3 · registry result, not featured evidence 10.1% NCT01952145 · Phase 3 · registry result, not featured evidence 5.5%Insulin Degludec/Liraglutide + Ora NCT01676116 · Phase 3 · registry result, not featured evidence · combination —Insulin Degludec/Liraglutide +OADs NCT01676116 · Phase 3 · registry result, not featured evidence · combination — NCT01570751 · Phase 3 · registry result, not featured evidence | 8.3%k NCT04760626 · Phase 3 show 14 more results3.7% NCT04460885 · Phase 3 · monotherapy · Type 2 Diabetes · phase 3 0% NCT06340854 · Phase 3 · combination · Type 2 Diabetes · phase 3 2% NCT04795531 · Phase 3 1.1% NCT04770532 · Phase 3 5.5% NCT04880850 · Phase 3 36.5%Insulin Icodec + Semaglutide NCT05813912 · Phase 3 · registry result, not featured evidence · combination —Insulin Icodec + Semaglutide: Trea NCT05813912 · Phase 3 · registry result, not featured evidence · combination 2% NCT05823948 · Phase 3 · registry result, not featured evidence 1.9%Insulin 287 (With 100% Loading Dos NCT03922750 · Phase 2 · registry result, not featured evidence 0%Insulin 287 (Without Loading Dose) NCT03922750 · Phase 2 · registry result, not featured evidence 2.4% NCT03751657 · Phase 2 · registry result, not featured evidence 2%Insulin 287 (Titration Algorithm A NCT03951805 · Phase 2 · registry result, not featured evidence 0%Insulin 287 (Titration Algorithm B NCT03951805 · Phase 2 · registry result, not featured evidence 0%Insulin 287 (Titration Algorithm C NCT03951805 · Phase 2 · registry result, not featured evidence |
| Discontinued due to AEs | 2.6%once dailyj NCT00982644 · Phase 3 · monotherapy · Type 2 Diabetes · phase 3 show 25 more results0% NCT01959529 · Phase 3 —once weekly NCT04538352 · Phase 4 · registry result, not featured evidence · combination — NCT03336528 · Phase 4 · registry result, not featured evidence — NCT04588259 · Phase 3 · registry result, not featured evidence — NCT04795531 · Phase 3 · registry result, not featured evidence 0.6%Insulin Degludec NCT03172494 · Phase 3 · registry result, not featured evidence 1.4%Insulin Degludec/Liraglutide NCT03172494 · Phase 3 · registry result, not featured evidence 0.7% NCT03175120 · Phase 3 · registry result, not featured evidence — NCT03078478 · Phase 3 · registry result, not featured evidence — NCT03268005 · Phase 3 · registry result, not featured evidence 0.4% NCT02501161 · Phase 3 · registry result, not featured evidence 0.4% NCT02906917 · Phase 3 · registry result, not featured evidence 2.2%Insulin Degludec NCT02607306 · Phase 3 · registry result, not featured evidence 2.9%Insulin Degludec/Liraglutide NCT02607306 · Phase 3 · registry result, not featured evidence — NCT02911948 · Phase 3 · registry result, not featured evidence — NCT02773368 · Phase 3 · registry result, not featured evidence 0.3%BID NCT02762578 · Phase 3 · registry result, not featured evidence 0.4% NCT02420262 · Phase 3 · registry result, not featured evidence 0%twice daily NCT02648217 · Phase 3 · registry result, not featured evidence 1%IDegLira NCT02298192 · Phase 3 · registry result, not featured evidence 2.9%IDegLira (1WT) NCT02298192 · Phase 3 · registry result, not featured evidence 3.2% NCT01952145 · Phase 3 · registry result, not featured evidence 0.3%Insulin Degludec/Liraglutide + Ora NCT01676116 · Phase 3 · registry result, not featured evidence · combination —Insulin Degludec/Liraglutide +OADs NCT01676116 · Phase 3 · registry result, not featured evidence · combination — NCT01570751 · Phase 3 · registry result, not featured evidence | —k NCT04760626 · Phase 3 show 14 more results— NCT04460885 · Phase 3 · monotherapy · Type 2 Diabetes · phase 3 — NCT06340854 · Phase 3 · combination · Type 2 Diabetes · phase 3 — NCT04795531 · Phase 3 — NCT04770532 · Phase 3 — NCT04880850 · Phase 3 —Insulin Icodec + Semaglutide NCT05813912 · Phase 3 · registry result, not featured evidence · combination —Insulin Icodec + Semaglutide: Trea NCT05813912 · Phase 3 · registry result, not featured evidence · combination — NCT05823948 · Phase 3 · registry result, not featured evidence 1.9%Insulin 287 (With 100% Loading Dos NCT03922750 · Phase 2 · registry result, not featured evidence 0%Insulin 287 (Without Loading Dose) NCT03922750 · Phase 2 · registry result, not featured evidence — NCT03751657 · Phase 2 · registry result, not featured evidence 2%Insulin 287 (Titration Algorithm A NCT03951805 · Phase 2 · registry result, not featured evidence 0%Insulin 287 (Titration Algorithm B NCT03951805 · Phase 2 · registry result, not featured evidence 0%Insulin 287 (Titration Algorithm C NCT03951805 · Phase 2 · registry result, not featured evidence |
| Serious AEs | 15.1%once dailyj NCT00982644 · Phase 3 · monotherapy · Type 2 Diabetes · phase 3 show 25 more results38.6% NCT01959529 · Phase 3 22.5%once weekly NCT04538352 · Phase 4 · registry result, not featured evidence · combination 3.7% NCT03336528 · Phase 4 · registry result, not featured evidence 6.7% NCT04588259 · Phase 3 · registry result, not featured evidence 5.1% NCT04795531 · Phase 3 · registry result, not featured evidence 4%Insulin Degludec NCT03172494 · Phase 3 · registry result, not featured evidence 3.9%Insulin Degludec/Liraglutide NCT03172494 · Phase 3 · registry result, not featured evidence 4.3% NCT03175120 · Phase 3 · registry result, not featured evidence 20.8% NCT03078478 · Phase 3 · registry result, not featured evidence 7% NCT03268005 · Phase 3 · registry result, not featured evidence 11.9% NCT02501161 · Phase 3 · registry result, not featured evidence 6.8% NCT02906917 · Phase 3 · registry result, not featured evidence 4.8%Insulin Degludec NCT02607306 · Phase 3 · registry result, not featured evidence 6.2%Insulin Degludec/Liraglutide NCT02607306 · Phase 3 · registry result, not featured evidence 2.9% NCT02911948 · Phase 3 · registry result, not featured evidence 2.9% NCT02773368 · Phase 3 · registry result, not featured evidence 4.4%BID NCT02762578 · Phase 3 · registry result, not featured evidence 4.8% NCT02420262 · Phase 3 · registry result, not featured evidence 3.8%twice daily NCT02648217 · Phase 3 · registry result, not featured evidence 6.7%IDegLira NCT02298192 · Phase 3 · registry result, not featured evidence 3.3%IDegLira (1WT) NCT02298192 · Phase 3 · registry result, not featured evidence 1.8% NCT01952145 · Phase 3 · registry result, not featured evidence —Insulin Degludec/Liraglutide + Ora NCT01676116 · Phase 3 · registry result, not featured evidence · combination 3.1%Insulin Degludec/Liraglutide +OADs NCT01676116 · Phase 3 · registry result, not featured evidence · combination 2.9% NCT01570751 · Phase 3 · registry result, not featured evidence | 8.3%k NCT04760626 · Phase 3 show 14 more results13% NCT04460885 · Phase 3 · monotherapy · Type 2 Diabetes · phase 3 7.8% NCT06340854 · Phase 3 · combination · Type 2 Diabetes · phase 3 5.1% NCT04795531 · Phase 3 8.4% NCT04770532 · Phase 3 7.6% NCT04880850 · Phase 3 —Insulin Icodec + Semaglutide NCT05813912 · Phase 3 · registry result, not featured evidence · combination 3.2%Insulin Icodec + Semaglutide: Trea NCT05813912 · Phase 3 · registry result, not featured evidence · combination 3.9% NCT05823948 · Phase 3 · registry result, not featured evidence 3.7%Insulin 287 (With 100% Loading Dos NCT03922750 · Phase 2 · registry result, not featured evidence 0%Insulin 287 (Without Loading Dose) NCT03922750 · Phase 2 · registry result, not featured evidence 1.6% NCT03751657 · Phase 2 · registry result, not featured evidence 5.9%Insulin 287 (Titration Algorithm A NCT03951805 · Phase 2 · registry result, not featured evidence 2%Insulin 287 (Titration Algorithm B NCT03951805 · Phase 2 · registry result, not featured evidence 0%Insulin 287 (Titration Algorithm C NCT03951805 · Phase 2 · registry result, not featured evidence |
| Most frequent reported AEs | once dailyj nasopharyngitis 23.9% headache 13.8% diarrhoea 10.8% NCT00982644 · Phase 3 · monotherapy · Type 2 Diabetes · phase 3 show 23 more resultsonce weekly pain 17.5% upper respiratory infection 0% NCT04538352 · Phase 4 · registry result, not featured evidence · combination emergency room visit for bilateral knee pain 1.2% emergency room visit for congestive heart failure 1.2% emergency room visit for wound infection 1.2% NCT03336528 · Phase 4 · registry result, not featured evidence diabetic retinopathy 14.7% hyperlipidaemia 14% upper respiratory tract infection 9.3% NCT04588259 · Phase 3 · registry result, not featured evidence covid-19 4.8% influenza 3.1% diabetic retinopathy 2% NCT04795531 · Phase 3 · registry result, not featured evidence upper respiratory tract infection 17.7% nasopharyngitis 5.1% diabetic retinopathy 3.4% NCT03172494 · Phase 3 · registry result, not featured evidence upper respiratory tract infection 18.4% diabetic retinopathy 7.8% lipase increased 7.5% NCT03172494 · Phase 3 · registry result, not featured evidence upper respiratory tract infection 12.6% lipase increased 12% diabetic retinopathy 11.6% NCT03175120 · Phase 3 · registry result, not featured evidence nasopharyngitis 19% upper respiratory tract infection 18.1% diarrhoea 9% NCT03078478 · Phase 3 · registry result, not featured evidence nasopharyngitis 5.9% NCT03268005 · Phase 3 · registry result, not featured evidence headache 11.5% nasopharyngitis 11.3% diarrhoea 7.7% NCT02501161 · Phase 3 · registry result, not featured evidence nasopharyngitis 13.6% headache 10.2% back pain 6% NCT02906917 · Phase 3 · registry result, not featured evidence viral upper respiratory tract infection 33.6% weight increased 7% pharyngitis 5.5% NCT02607306 · Phase 3 · registry result, not featured evidence viral upper respiratory tract infection 38.5% constipation 9.8% diabetic retinopathy 6.2% NCT02607306 · Phase 3 · registry result, not featured evidence viral upper respiratory tract infection 20% diabetic retinopathy 16.2% diarrhoea 14.3% NCT02911948 · Phase 3 · registry result, not featured evidence headache 8.6% viral upper respiratory tract infection 7.7% lipase increased 5.7% NCT02773368 · Phase 3 · registry result, not featured evidence BID upper respiratory tract infection 21.1% diabetic retinopathy 10% viral upper respiratory tract infection 2.5% NCT02762578 · Phase 3 · registry result, not featured evidence nausea 11.1% influenza 7.1% diarrhoea 6.3% NCT02420262 · Phase 3 · registry result, not featured evidence twice daily blood glucose decreased 35.4% upper respiratory tract infection 6.2% pyrexia 3.1% NCT02648217 · Phase 3 · registry result, not featured evidence lipase increased 10% headache 9.3% nasopharyngitis 8.9% NCT01676116 · Phase 3 · registry result, not featured evidence · combination nasopharyngitis 1.4% NCT01570751 · Phase 3 · registry result, not featured evidence | show 13 more resultscovid-19 17.7% back pain 8.1% diarrhoea 7.9% NCT04460885 · Phase 3 · monotherapy · Type 2 Diabetes · phase 3 nasopharyngitis 13.6% diarrhoea 5.3% diabetic retinopathy 2.9% NCT06340854 · Phase 3 · combination · Type 2 Diabetes · phase 3 nausea 19.1% vomiting 8.5% upper respiratory tract infection 7.4% NCT05813912 · Phase 3 · registry result, not featured evidence · combination nasopharyngitis 13.7% covid-19 9.8% back pain 7.8% NCT05823948 · Phase 3 · registry result, not featured evidence nasopharyngitis 14.8% medical device site haemorrhage 9.3% headache 5.6% NCT03922750 · Phase 2 · registry result, not featured evidence nasopharyngitis 14% hypertension 6% influenza 6% NCT03922750 · Phase 2 · registry result, not featured evidence headache 11.2% nasopharyngitis 8% upper respiratory tract infection 5.6% NCT03751657 · Phase 2 · registry result, not featured evidence back pain 9.8% nasopharyngitis 9.8% headache 0% NCT03951805 · Phase 2 · registry result, not featured evidence nasopharyngitis 13.7% headache 5.9% back pain 3.9% NCT03951805 · Phase 2 · registry result, not featured evidence headache 9.6% nasopharyngitis 3.8% back pain 1.9% NCT03951805 · Phase 2 · registry result, not featured evidence |
Notes
- aThis study reports multiple eligible drug arms; no representative arm has been reviewed.
- bPopulation comparability has not been reviewed for both studies.
- cTreatment context has not been resolved for both arms.
- dAssessment timepoints differ: 32 weeks versus 52 weeks.
- eTrial phases differ: Phase 3 versus Phase 2.
- fPopulation context differs: registered conditions differ.
- gAssessment timepoints differ: 16 weeks versus 26 weeks.
- hThe assessment timepoint is not available for both results.
- iAssessment timepoints differ: 52 weeks versus 26 weeks.
- jPopulation comparability has not been reviewed for 25 of these studies.
- kPopulation comparability has not been reviewed for 13 of these studies.
Reported by one asset only
Endpoints only one of the selected assets measured, so there is nothing to compare them against.
insulin degludec
+ 102 further endpoints in the CSV export.
insulin icodec
show 2 more results
show 2 more results
show 5 more results
The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: insulin degludec's landscape · insulin icodec's landscape